Checkpoint Therapeutics’ (CKPT) “Buy” Rating Reiterated at D. Boral Capital

D. Boral Capital reissued their buy rating on shares of Checkpoint Therapeutics (NASDAQ:CKPT) in a research note issued to investors on Monday,Benzinga reports. They currently have a $4.80 price target on the stock, down from their previous price target of $9.00.

A number of other analysts have also issued reports on CKPT. Lake Street Capital boosted their target price on Checkpoint Therapeutics from $4.00 to $7.00 and gave the company a “buy” rating in a research report on Monday, December 16th. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price objective on shares of Checkpoint Therapeutics in a research report on Monday, December 16th.

Checkpoint Therapeutics Stock Down 0.5 %

Shares of NASDAQ CKPT opened at $3.98 on Monday. The firm has a market cap of $194.36 million, a price-to-earnings ratio of -2.16 and a beta of 1.41. Checkpoint Therapeutics has a 52-week low of $1.38 and a 52-week high of $4.50. The business’s 50 day moving average is $3.13 and its two-hundred day moving average is $3.10.

Insider Transactions at Checkpoint Therapeutics

In related news, CFO William Garrett Gray sold 268,432 shares of the stock in a transaction on Wednesday, December 18th. The stock was sold at an average price of $4.01, for a total value of $1,076,412.32. Following the transaction, the chief financial officer now owns 1,032,754 shares of the company’s stock, valued at $4,141,343.54. This represents a 20.63 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO James F. Oliviero III sold 220,230 shares of the stock in a transaction on Thursday, December 19th. The shares were sold at an average price of $3.38, for a total value of $744,377.40. Following the completion of the transaction, the chief executive officer now directly owns 3,194,583 shares in the company, valued at $10,797,690.54. This trade represents a 6.45 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 582,336 shares of company stock valued at $2,156,801. 2.10% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Checkpoint Therapeutics

Several large investors have recently bought and sold shares of CKPT. 683 Capital Management LLC acquired a new position in Checkpoint Therapeutics in the fourth quarter valued at $522,000. Geode Capital Management LLC boosted its stake in shares of Checkpoint Therapeutics by 41.2% during the third quarter. Geode Capital Management LLC now owns 427,651 shares of the company’s stock worth $958,000 after buying an additional 124,787 shares during the period. OMERS ADMINISTRATION Corp acquired a new stake in shares of Checkpoint Therapeutics during the fourth quarter worth about $374,000. Bank of America Corp DE boosted its stake in shares of Checkpoint Therapeutics by 30,216.8% during the fourth quarter. Bank of America Corp DE now owns 90,041 shares of the company’s stock worth $288,000 after buying an additional 89,744 shares during the period. Finally, Wealth Enhancement Advisory Services LLC boosted its stake in shares of Checkpoint Therapeutics by 160.0% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 130,000 shares of the company’s stock worth $291,000 after buying an additional 80,000 shares during the period. Institutional investors and hedge funds own 22.00% of the company’s stock.

About Checkpoint Therapeutics

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.